Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1624 1625
This examiner grants 76% of resolved cases
Rehana Ismail works in Tech Center 1600 and Art Unit 1624. She has 99 resolved cases. Her allowance rate is 75.8 percent, which is a high grant rate for her docket. This 75.8 percent figure suggests that the examiner is generally receptive to patent applications, with three out of every four resolved matters resulting in a notice of allowance for the applicant.
The interview lift is 34.8 percent. This 34.8 percent lift is significant, suggesting that interviews are a very effective tool for this examiner. Practitioners should utilize interviews to improve the 75.8 percent baseline allowance rate, as the data shows that personal engagement with the examiner can substantially boost the chances of overcoming rejections and reaching a favorable conclusion.
The median days to allowance is 1290. This 1290 day period is the median time to grant for successful applications. Applicants should expect a 1290 day pendency for their cases, which reflects the typical duration of the prosecution cycle from the initial filing to the final issuance of a patent in this art unit.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18566270 | COMPOSITIONS AND METHODS FOR TREATING CELIAC DISEASE | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 18708955 | TREATMENT OF MYOTONIC DISORDERS | Non-Final OA | University of Rochester |
| 17910723 | METHODS OF MODULATING T-CELL ACTIVATION USING CARBORANES AND CARBORANE ANALOGS | Non-Final OA | Ohio State Innovation Foundation |
| 18933587 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | Non-Final OA | ELI LILLY AND COMPANY |
| 18826275 | AT2R ANTAGONISTS AND USES THEREOF | Non-Final OA | Eli Lilly and Company |
| 17995914 | COMPOUNDS FOR THE TREATMENT OF SARS | Final Rejection | Purdue Research Foundation |
| 18574130 | PEST CONTROL COMPOSITION AND PEST CONTROL METHOD | Non-Final OA | SUMITOMO CHEMICAL COMPANY, LIMITED |
| 18294472 | DISCOVERY OF A F-ATP SYNTHASE INHIBITOR FOR THE TREATMENT OF MYCOBACTERIUM ABSCESSUS DISEASES | Non-Final OA | Nanyang Technological University |
| 18934390 | HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | Non-Final OA | BeiGene, Ltd. |
| 18792377 | MULTIDOSE OPHTHALMIC COMPOSITIONS | Non-Final OA | Oculis Operations Sàrl |
| 18259112 | SUBSTITUTED IMIDAZO[1,5-b]PYRIDAZINE COMPOUNDS AS KINASE INHIBITORS AND USE THEREOF | Non-Final OA | IMPACT THERAPEUTICS (SHANGHAI), INC |
| 18574162 | USE OF FOLATE DERIVATIVE IN PREPARATION OF DRUG FOR TREATING CONTACT LENS DISCOMFORT AND DRY EYE | Non-Final OA | LIANYUNGANG JINKANG HEXIN PHARMACEUTICAL CO., LTD. |
| 18007935 | RIGID CANNABIDIOL ANALOGUES AS POTENT MODULATORS OF CANNABINOID RECEPTORS AND USES THEREOF | Non-Final OA | LONDON PHARMACEUTICALS AND RESEARCH CORPORATION |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy